The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients
Rodriguez-French, Amalia, Boghossian, Jack, Gray, Glenda E, Nadler, Jeffrey P, Quinones, Arnaldo R, Sepulveda, Gladys E, Millard, Judith M, Wannamaker, Paul G
Published in Journal of acquired immune deficiency syndromes (1999) (01.01.2004)
Published in Journal of acquired immune deficiency syndromes (1999) (01.01.2004)
Get more information
Journal Article
A prospective, 96‐week study of the impact of Trizivir®, Combivir®/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral‐naive patients: effect of sex and ethnicity
Kumar, PN, Rodriguez‐French, A, Thompson, MA, Tashima, KT, Averitt, D, Wannamaker, PG, Williams, VC, Shaefer, MS, Pakes, GE, Pappa, KA
Published in HIV medicine (01.03.2006)
Published in HIV medicine (01.03.2006)
Get full text
Journal Article
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial
Fischl, Margaret A, Burnside, Jr, Alfred E, Farthing, Charles E, Thompson, Melanie A, Bellos, Nicholaos C, Williams, Vanessa C, Kauf, Teresa L, Wannamaker, Paul G, Shaefer, Mark S
Published in Pharmacotherapy (01.11.2003)
Published in Pharmacotherapy (01.11.2003)
Get more information
Journal Article